Baker David, Pryce Gareth, Jackson Samuel J, Bolton Chris, Giovannoni Gavin
Department of Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
Department of Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
Mult Scler Relat Disord. 2012 Apr;1(2):64-75. doi: 10.1016/j.msard.2011.11.001. Epub 2012 Jan 18.
Cannabis-based medicines have recently been approved for the treatment of pain and spasticity in multiple sclerosis (MS). This supports the original perceptions of people with MS, who were using illegal street cannabis for symptom control and pre-clinical testing in animal models of MS. This activity is supported both by the biology of the disease and the biology of the cannabis plant and the endocannabinoid system. MS results from disease that impairs neurotransmission and this is controlled by cannabinoid receptors and endogenous cannabinoid ligands. This can limit spasticity and may also influence the processes that drive the accumulation of progressive disability.
基于大麻的药物最近已被批准用于治疗多发性硬化症（MS）的疼痛和痉挛。这支持了MS患者最初的认知，他们曾使用非法街头大麻来控制症状并在MS动物模型中进行临床前测试。这种作用既得到该疾病生物学特性的支持，也得到大麻植物生物学特性和内源性大麻素系统的支持。MS是由损害神经传递的疾病引起的，而这由大麻素受体和内源性大麻素配体控制。这可以限制痉挛，还可能影响导致进行性残疾累积的过程。
